MedDataX Logo

A Multiple Dose Study Of PF-04620110 In Healthy Overweight Or Obese Subjects

NCT ID: NCT01146327

Last Updated: 2011-04-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-06-30

Study Completion Date

2011-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

PF-04620110 is a novel compound proposed for the treatment of Type 2 diabetes mellitus. The primary purpose of this trial is to evaluate the safety and tolerability, and pharmacodynamics, of multiple oral doses of PF-04620110.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Single Dose Study Of PF-04620110 In Healthy Subjects

NCT01166217

Healthy
COMPLETED PHASE1

A Study Of PF-04620110 As A Modified-Release Formulation In Healthy Overweight Or Obese Subjects

NCT01474941

Healthy
COMPLETED PHASE1

A First-In-Human Study of the Study Medicine, Called PF-07291177, in Healthy Adult Participants

NCT05434091

Healthy Participants
WITHDRAWN PHASE1

A Single Dose Study Of PF-05161704 In Healthy Volunteers

NCT01183715

Diabetes Mellitus, Type 2
COMPLETED PHASE1

A Study To Evaluate The Effects Of PF-05175157 In Healthy Volunteers

NCT01537497

Diabetes Mellitus, Type 2
COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PF-04620110

Group Type EXPERIMENTAL

PF-04620110

Intervention Type DRUG

Multiple oral doses of 5 mg of PF-04620110 will be given once daily for 2 weeks.

PF-04620110

Intervention Type DRUG

Multiple oral doses of 1.5 mg of PF-04620110 will be given twice daily for 2 weeks.

PF-04620110

Intervention Type DRUG

Multiple oral doses of 3 mg of PF-04620110 will be given once daily for 2 weeks.

PF-04620110

Intervention Type DRUG

Multiple oral doses of 2.5 mg of PF-04620110 will be given twice daily for 2 weeks.

Placebo Comparator

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Multiple oral doses of placebo will be given once daily for 2 weeks.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PF-04620110

Multiple oral doses of 5 mg of PF-04620110 will be given once daily for 2 weeks.

Intervention Type DRUG

PF-04620110

Multiple oral doses of 1.5 mg of PF-04620110 will be given twice daily for 2 weeks.

Intervention Type DRUG

PF-04620110

Multiple oral doses of 3 mg of PF-04620110 will be given once daily for 2 weeks.

Intervention Type DRUG

PF-04620110

Multiple oral doses of 2.5 mg of PF-04620110 will be given twice daily for 2 weeks.

Intervention Type DRUG

Placebo

Multiple oral doses of placebo will be given once daily for 2 weeks.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy male and/or female subjects between the ages of 18 and 55 years
* Body Mass Index (BMI) of 26.5 to 35.5 kg/m2; and a total body weight \>50 kg (110 lbs).

Exclusion Criteria

* Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing) disease or clinical findings at screening.
Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Bristol-Myers Squibb

INDUSTRY

Sponsor Role collaborator

Pfizer

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Pfizer, Inc.

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pfizer CT.gov Call Center

Role: STUDY_DIRECTOR

Pfizer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Pfizer Investigational Site

Brussels, , Belgium

Site Status

Pfizer Investigational Site

Singapore, , Singapore

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Belgium Singapore

Related Links

Access external resources that provide additional context or updates about the study.

https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B0961010&StudyName=A%20Multiple%20Dose%20Study%20Of%20PF-04620110%20In%20Healthy%20Overweight%20Or%20Obese%20Subjects

To obtain contact information for a study center near you, click here.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

B0961010

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

A Multiple Dose Safety And Pharmacokinetic (PK) Study Of PF-06427878 In Overweight-Obese, Otherwise Healthy Subjects
NCT02855177 COMPLETED PHASE1
A Study To Evaluate the Safety, Tolerability, And Pharmacokinetics Of PF-06266047 In Healthy Adult Subjects
NCT02539550 COMPLETED PHASE1
A Phase 1 Study To Estimate The Relative Bioavailability And Food Effect Of PF-04620110 In Healthy Adult Subjects
NCT01064492 COMPLETED PHASE1
A Study To Evaluate The Safety, Tolerability And Plasma Drug Levels Following A Single Dose Of PF-04995274 In Healthy Adult Volunteers
NCT01091272 COMPLETED PHASE1
Single Dose Study of PF-04991532 in Healthy Subjects
NCT01102673 COMPLETED PHASE1
A Study Of PF-05175157 In Healthy Volunteers
NCT01274663 COMPLETED PHASE1
A Study To Evaluate PF-05175157 In Healthy Volunteers
NCT01433380 COMPLETED PHASE1
A Study to Evaluate Safety, Toleration and Time Course of Plasma Concentration of Multiple Oral Doses of PF-06273340 in Healthy Subjects of Two AgeGroups, Aged 18-55 Years (Group 1) and Aged 56-75 Years (Group 2)
NCT01934738 COMPLETED PHASE1
A Phase 1 Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-05230907 In Healthy Volunteers
NCT01897142 COMPLETED PHASE1
A Study In Healthy People To Evaluate Safety, Toleration, Pharmacokinetics And Pharmacodynamics Of Multiple Oral Doses Of PF-06743649
NCT02151617 COMPLETED PHASE1
A Study To Assess The Safety, Tolerability, And Pharmacokinetics (PK) Of Multiple Doses Of PF-06865571 In Healthy, Including Overweight And Obese, Adult Subjects
NCT03230383 COMPLETED PHASE1
A Single Oral Dose Study Of PF-06427878 In Healthy Adult Subjects
NCT02208284 COMPLETED PHASE1
A Study In Healthy People To Evaluate Safety, Toleration And Time Course Of Plasma Concentration Of Multiple Oral Doses Of PF-04895162
NCT01691274 COMPLETED PHASE1
A Multiple Oral Doses Study Of PF-06427878 In Healthy Adult Subjects
NCT02391623 COMPLETED PHASE1
Single Dose Study of PF-05230907 in Healthy Japanese Subjects
NCT02537002 COMPLETED PHASE1
First in Human Study for PF-06667272
NCT03126149 COMPLETED PHASE1
A Single Dose Study Of PF-06291874 In Healthy Adult Subjects
NCT01499017 TERMINATED PHASE1
Single Dose Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06291874 In Healthy Adult Subjects
NCT01794364 COMPLETED PHASE1
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PF-06842874 in Healthy Participants
NCT04124653 COMPLETED PHASE1
A Multiple Dose Study To Determine Safety, Tolerability, and Pharmacokinetics Of PF-04634817 In Healthy Adult Subjects
NCT01140672 COMPLETED PHASE1
Multiple Dose Study Of PF-05231023 In Adult Subjects Who Have Poor Lipid Control With And Without Type 2 Diabetes Mellitus
NCT01673178 COMPLETED PHASE1
Study To Evaluate Safety, Tolerability, And Pharmacokinetics Of PF-06473871 In Normal Healthy Adults
NCT01753791 COMPLETED PHASE1
A Study to Learn How Different Amounts and Forms of the Study Medicine Called PF-06414300 Act in Healthy Adults
NCT06659250 COMPLETED PHASE1
A Single Ascending Dose Study To Evaluate Safety And Pharmacokinetics Of Compound PF-06648671 In Healthy Subjects
NCT02316756 COMPLETED PHASE1
Study of Multiple Oral Doses of PF-06835919 in Healthy Adult Japanese Participants
NCT04427917 COMPLETED PHASE1